These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36265311)

  • 1. Nonsense codons suppression. An acute toxicity study of three optimized TRIDs in murine model, safety and tolerability evaluation.
    Corrao F; Zizzo MG; Tutone M; Melfi R; Fiduccia I; Carollo PS; Leonardo AD; Caldara G; Perriera R; Pace A; Belmonte B; Sammataro S; Pibiri I; Lentini L
    Biomed Pharmacother; 2022 Dec; 156():113886. PubMed ID: 36265311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Readthrough Approach Using NV Translational Readthrough-Inducing Drugs (TRIDs): A Study of the Possible Off-Target Effects on Natural Termination Codons (NTCs) on TP53 and Housekeeping Gene Expression.
    Perriera R; Vitale E; Pibiri I; Carollo PS; Ricci D; Corrao F; Fiduccia I; Melfi R; Zizzo MG; Tutone M; Pace A; Lentini L
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies against Nonsense: Oxadiazoles as Translational Readthrough-Inducing Drugs (TRIDs).
    Campofelice A; Lentini L; Di Leonardo A; Melfi R; Tutone M; Pace A; Pibiri I
    Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31284579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigating the Inhibition of FTSJ1, a Tryptophan tRNA-Specific 2'-O-Methyltransferase by NV TRIDs, as a Mechanism of Readthrough in Nonsense Mutated CFTR.
    Carollo PS; Tutone M; Culletta G; Fiduccia I; Corrao F; Pibiri I; Di Leonardo A; Zizzo MG; Melfi R; Pace A; Almerico AM; Lentini L
    Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Nonsense: Optimization of 1,2,4-Oxadiazole TRIDs to Rescue CFTR Expression and Functionality in Cystic Fibrosis Cell Model Systems.
    Pibiri I; Melfi R; Tutone M; Di Leonardo A; Pace A; Lentini L
    Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32899265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceuticals Promoting Premature Termination Codon Readthrough: Progress in Development.
    Li S; Li J; Shi W; Nie Z; Zhang S; Ma F; Hu J; Chen J; Li P; Xie X
    Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ataluren and aminoglycosides stimulate read-through of nonsense codons by orthogonal mechanisms.
    Ng MY; Li H; Ghelfi MD; Goldman YE; Cooperman BS
    Proc Natl Acad Sci U S A; 2021 Jan; 118(2):. PubMed ID: 33414181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rescuing the CFTR protein function: Introducing 1,3,4-oxadiazoles as translational readthrough inducing drugs.
    Pibiri I; Lentini L; Melfi R; Tutone M; Baldassano S; Ricco Galluzzo P; Di Leonardo A; Pace A
    Eur J Med Chem; 2018 Nov; 159():126-142. PubMed ID: 30278331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors Affecting Readthrough of Natural Versus Premature Termination Codons.
    Beryozkin A; Nagel-Wolfum K; Banin E; Sharon D
    Adv Exp Med Biol; 2023; 1415():149-155. PubMed ID: 37440028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toward a rationale for the PTC124 (Ataluren) promoted readthrough of premature stop codons: a computational approach and GFP-reporter cell-based assay.
    Lentini L; Melfi R; Di Leonardo A; Spinello A; Barone G; Pace A; Palumbo Piccionello A; Pibiri I
    Mol Pharm; 2014 Mar; 11(3):653-64. PubMed ID: 24483936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of premature stop codon readthrough in the CFTR gene by Ataluren (PTC124) derivatives.
    Pibiri I; Lentini L; Melfi R; Gallucci G; Pace A; Spinello A; Barone G; Di Leonardo A
    Eur J Med Chem; 2015 Aug; 101():236-44. PubMed ID: 26142488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ataluren for the Treatment of Usher Syndrome 2A Caused by Nonsense Mutations.
    Samanta A; Stingl K; Kohl S; Ries J; Linnert J; Nagel-Wolfrum K
    Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31842393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis.
    Sermet-Gaudelus I; Boeck KD; Casimir GJ; Vermeulen F; Leal T; Mogenet A; Roussel D; Fritsch J; Hanssens L; Hirawat S; Miller NL; Constantine S; Reha A; Ajayi T; Elfring GL; Miller LL
    Am J Respir Crit Care Med; 2010 Nov; 182(10):1262-72. PubMed ID: 20622033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A High-Throughput Assay for In Vitro Determination of Release Factor-Dependent Peptide Release from a Pretermination Complex by Fluorescence Anisotropy-Application to Nonsense Suppressor Screening and Mechanistic Studies.
    Ghelfi MD; Bhat SY; Li H; Cooperman BS
    Biomolecules; 2023 Jan; 13(2):. PubMed ID: 36830611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Translational Read-Through Drugs (TRIDs) Are Able to Restore Protein Expression and Ciliogenesis in Fibroblasts of Patients with Retinitis Pigmentosa Caused by a Premature Termination Codon in
    Beryozkin A; Samanta A; Gopalakrishnan P; Khateb S; Banin E; Sharon D; Nagel-Wolfrum K
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrity and Stability of PTC Bearing CFTR mRNA and Relevance to Future Modulator Therapies in Cystic Fibrosis.
    Clarke LA; Luz VCC; Targowski S; Ramalho SS; Farinha CM; Amaral MD
    Genes (Basel); 2021 Nov; 12(11):. PubMed ID: 34828417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacophore-Based Design of New Chemical Scaffolds as Translational Readthrough-Inducing Drugs (TRIDs).
    Tutone M; Pibiri I; Perriera R; Campofelice A; Culletta G; Melfi R; Pace A; Almerico AM; Lentini L
    ACS Med Chem Lett; 2020 May; 11(5):747-753. PubMed ID: 32435380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor.
    Xue X; Mutyam V; Tang L; Biswas S; Du M; Jackson LA; Dai Y; Belakhov V; Shalev M; Chen F; Schacht J; J Bridges R; Baasov T; Hong J; Bedwell DM; Rowe SM
    Am J Respir Cell Mol Biol; 2014 Apr; 50(4):805-16. PubMed ID: 24251786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional Restoration of CFTR Nonsense Mutations in Intestinal Organoids.
    de Poel E; Spelier S; Suen SWF; Kruisselbrink E; Graeber SY; Mall MA; Weersink EJM; van der Eerden MM; Koppelman GH; van der Ent CK; Beekman JM
    J Cyst Fibros; 2022 Mar; 21(2):246-253. PubMed ID: 34666947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ataluren/ivacaftor combination therapy: Two N-of-1 trials in cystic fibrosis patients with nonsense mutations.
    Peabody Lever JE; Mutyam V; Hathorne HY; Peng N; Sharma J; Edwards LJ; Rowe SM
    Pediatr Pulmonol; 2020 Jul; 55(7):1838-1842. PubMed ID: 32281737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.